Oura launched its first proprietary AI model on February 24, 2026, built specifically to give personalized cycle, fertility, pregnancy and menopause guidance using a member's own biometric data — all processed on Oura's own servers rather than sent to outside AI providers.
Nvidia unveiled a healthcare robotics platform, including a hospital digital-twin blueprint called Rheo, designed to train clinical robots in simulation before they ever touch a real patient.
Eli Lilly has switched on LillyPod, a 1,016-GPU NVIDIA supercomputer delivering over 9,000 petaflops — a bet that owning frontier-scale AI compute is now essential to compete in drug discovery.
Guidehealth, RediMinds and SandsRx are the first organizations to earn URAC's new Health Care AI Accreditation, a voluntary credential meant to fill the gap regulators haven't closed.
Oracle Health's AI-powered patient portal, now generally available across the US, lets patients ask plain-language questions about labs, medications and diabetes management directly from their EHR, with citations and highlighting meant to keep AI answers traceable rather than opaque.
Elucid closed a $55 million Series D on September 2, 2026, bringing total funding to about $185 million to expand its FDA-cleared Plaque-IQ AI, which reads coronary CT scans to classify dangerous heart plaque, plus a new FFR-CT tool awaiting FDA review.
Google and Character.AI settled five lawsuits, including the Sewell Setzer III wrongful-death case, alleging AI companion chatbots contributed to harm and death among teenagers.
Dartmouth's Therabot, developed by psychiatry researchers Michael Heinz and Nicholas Jacobson, is being held up as an example of an AI mental health chatbot built and validated through clinical research rather than consumer trial and error.
New multicenter data presented at the Society of Critical Care Medicine's 2026 Critical Care Congress show Cytovale's AI-interpreted IntelliSep sepsis test cut mortality 19% across four expansion hospitals and more than 34,000 ED patients — though the results come from vendor-linked, pre-post analysis rather than an independent randomized trial.
Oura has built a proprietary AI model dedicated to women's health that blends clinician-vetted research with a user's own biometric data, aiming to give more trustworthy answers on cycles, pregnancy and menopause than generic search results.